Patents Assigned to ARCH CANCER THERAPEUTICS, INC.
-
Patent number: 11083773Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: GrantFiled: September 13, 2018Date of Patent: August 10, 2021Assignee: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
-
Publication number: 20200038473Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: ApplicationFiled: September 13, 2018Publication date: February 6, 2020Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
-
Publication number: 20170072006Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: ApplicationFiled: August 31, 2016Publication date: March 16, 2017Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
-
Patent number: 9464114Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: GrantFiled: February 13, 2015Date of Patent: October 11, 2016Assignee: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
-
Publication number: 20150225459Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: ApplicationFiled: February 13, 2015Publication date: August 13, 2015Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
-
Patent number: 9095541Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).Type: GrantFiled: June 2, 2011Date of Patent: August 4, 2015Assignee: Arch Cancer Therapeutics, Inc.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger
-
Patent number: 8530429Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). Also disclosed are a phage-display screening method for identifying such therapeutic peptides, and peptides that hind specifically to BTICs or HIGCs.Type: GrantFiled: November 19, 2010Date of Patent: September 10, 2013Assignee: Arch Cancer Therapeutics, Inc.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger
-
Publication number: 20110274619Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).Type: ApplicationFiled: June 2, 2011Publication date: November 10, 2011Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger
-
Publication number: 20110129418Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). Also disclosed are a phage-display screening method for identifying such therapeutic peptides, and peptides that hind specifically to BTICs or HIGCs.Type: ApplicationFiled: November 19, 2010Publication date: June 2, 2011Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger